UCB CELLTECH
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 1925-01-01
- Employees
- 11
- Market Cap
- -
A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- UCB Celltech
- Target Recruit Count
- 12
- Registration Number
- NCT05028127
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- UCB Celltech
- Target Recruit Count
- 27
- Registration Number
- NCT02610543
- Locations
- 🇫🇷
Ss0004 34, Brest, France
🇫🇷Ss0004 30, Le Kremlin-Bicêtre, France
🇫🇷Ss0004 35, Strasbourg, France
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis
- First Posted Date
- 2015-08-20
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- UCB Celltech
- Target Recruit Count
- 39
- Registration Number
- NCT02529956
- Locations
- 🇬🇧
1, Harrow, United Kingdom
Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Certolizumab PegolBiological: BimekizumabOther: Placebo
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- UCB Celltech
- Target Recruit Count
- 159
- Registration Number
- NCT02430909
- Locations
- 🇨🇿
Ra0123 101, Praha 7, Czechia
🇭🇺Ra0123 203, Balatonfured, Hungary
🇭🇺Ra0123 201, Budapest, Hungary
A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: UCB7665 Intravenous 1Biological: UCB7665 Intravenous 3Biological: Subcutaneous PlaceboBiological: UCB7665 Intravenous 2Biological: Intravenous PlaceboBiological: UCB7665 Intravenous 4Biological: UCB7665 Intravenous 5Biological: UCB7665 Subcutaneous 1Biological: UCB7665 Subcutaneous 2
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- UCB Celltech
- Target Recruit Count
- 41
- Registration Number
- NCT02220153
- Locations
- 🇬🇧
001, Harrow, Middlesex, United Kingdom
Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- UCB Celltech
- Target Recruit Count
- 60
- Registration Number
- NCT02207595
- Locations
- 🇬🇧
1, Harrow, United Kingdom
Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis
Phase 1
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: UCB4940 160 mgDrug: UCB4940 80 mgDrug: UCB4940 40 mgDrug: UCB4940 320 mgDrug: UCB4940 240 mgDrug: UCB4940 560 mgOther: Placebo
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- UCB Celltech
- Target Recruit Count
- 53
- Registration Number
- NCT02141763
- Locations
- 🇧🇬
001, Sofia, Bulgaria
🇲🇩002, St. Chisinau, Moldova, Republic of
🇬🇧003, Manchester, United Kingdom
The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- UCB Celltech
- Target Recruit Count
- 99
- Registration Number
- NCT00899678